Ionis Pharmaceuticals Q2 2025 Earnings Call Transcript
ByAinvest
Wednesday, Jul 30, 2025 4:43 pm ET1min read
IONS--
The strong performance was driven by the successful launch of Tryngolza (olezarsen), the first FDA-approved treatment for familial chylomicronemia syndrome, and increased royalty and R&D revenues. Tryngolza generated net product sales of $19 million in the second quarter, contributing to the overall revenue growth [1].
The company also highlighted progress in its clinical pipeline, including positive data from the CARMINE trial for AKCEA-APOCIII-LRx. Additionally, the drug received a positive opinion from the Committee for Medicinal Products for Human Use, paving the way for its approval in Europe [1].
Ionis raised its fiscal 2025 sales guidance to $825 million-$850 million, compared to the previous estimate of $725 million-$750 million. The company expects a 2025 adjusted operating loss of $300 million-$325 million, with cash, cash equivalents, and short-term investments of around $2 billion [1].
The stock price of Ionis Pharmaceuticals has seen a positive reaction to the earnings report, with the stock up 5.23% at $43.65 at publication [1].
References:
[1] https://www.benzinga.com/markets/earnings/25/07/46733874/ionis-posts-surprise-q2-profit-double-revenues-on-stronger-sales-from-newly-approved-genetic-disease-drug
[2] https://www.gurufocus.com/news/3016122/ionis-reports-second-quarter-2025-financial-results-and-highlights-progress-on-key-programs
Ionis Pharmaceuticals reported Q2 2025 earnings, with CEO Brett Monia and CFO Beth Hougen discussing financial results and product developments. The company's net revenue increased to $133.4 million, driven by strong sales of SPINRAZA and TEGSEDI. Ionis also highlighted progress in its clinical pipeline, including positive data from the CARMINE trial for AKCEA-APOCIII-LRx. The company's non-GAAP net income was $32.1 million, or $0.88 per share.
Ionis Pharmaceuticals Inc. (IONS) reported its second-quarter 2025 financial results, with a significant improvement in earnings and revenue. The company's adjusted earnings per share (EPS) came in at $0.85, compared to the expected loss of $0.52, and the revenue reached $452 million, surpassing the consensus estimate of $282.95 million [1].The strong performance was driven by the successful launch of Tryngolza (olezarsen), the first FDA-approved treatment for familial chylomicronemia syndrome, and increased royalty and R&D revenues. Tryngolza generated net product sales of $19 million in the second quarter, contributing to the overall revenue growth [1].
The company also highlighted progress in its clinical pipeline, including positive data from the CARMINE trial for AKCEA-APOCIII-LRx. Additionally, the drug received a positive opinion from the Committee for Medicinal Products for Human Use, paving the way for its approval in Europe [1].
Ionis raised its fiscal 2025 sales guidance to $825 million-$850 million, compared to the previous estimate of $725 million-$750 million. The company expects a 2025 adjusted operating loss of $300 million-$325 million, with cash, cash equivalents, and short-term investments of around $2 billion [1].
The stock price of Ionis Pharmaceuticals has seen a positive reaction to the earnings report, with the stock up 5.23% at $43.65 at publication [1].
References:
[1] https://www.benzinga.com/markets/earnings/25/07/46733874/ionis-posts-surprise-q2-profit-double-revenues-on-stronger-sales-from-newly-approved-genetic-disease-drug
[2] https://www.gurufocus.com/news/3016122/ionis-reports-second-quarter-2025-financial-results-and-highlights-progress-on-key-programs
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet